 effects cyproheptadine locomotion spasticity patients spinal cord injuries effects cyproheptadine serotonergic antagonist patients spastic paresis spinal origin patients double blind crossover trial maximal mg/day patients spasticity locomotor function patients open trial cyproheptadine minimum months optimal dose Patients treadmill full weight possible body overhead harness system Cyproheptadine sustained ankle clonus episodes spontaneous spasms patients manifestations spasticity patients body weight support BWS locomotion full weight cyproheptadine therapy normal timing EMG patterns patients cyproheptadine therapy temporal distance changes improvement joint angular displacement contrast patients marginal changes EMG kinematic pattern speed preliminary results cyproheptadine spasticity enhance locomotor function spinal cord patients